Barclays starts coverage on Natera with 'outperform' rating
24/01/2025 12:56
** Brokerage Barclays starts coverage on genetic testing
firm Natera NTRA.O with "overweight" rating and sets PT at
$200
** PT represents 16.4% upside to stock's last close
** Brokerage says NTRA has a "compelling long-term
investment" opportunity due to its portfolio diversification in
high-growth markets with significant potential for market
expansion
** Barclays says it is confident the company will
continue to report strong results through 2025 driven by sales
growth and price increases across its portfolio
** NTRA more than tripled in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Natera
See all newsBrief: FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay
Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers